Marchant Gary E, Campos-Outcalt Doug E, Lindor Rachel A
University of Arizona, 550 E. Van Buren Street, Phoenix, AZ 85004, USA.
Sandra Day O'Connor College of Law, Arizona State University, PO Box 877906, Tempe, AZ 85287-7906, USA.
Per Med. 2011 Jul;8(4):457-467. doi: 10.2217/pme.11.33.
Liability is likely to be a major driver for the future direction and implementation of personalized medicine, spurring the adoption of genetic tests and other pharmacogenomic technologies, in some cases appropriately, and in other cases prematurely or as inefficient defensive medicine. While all entities in the personalized medicine chain will face liability risks, physicians will be at the greatest risk owing to their lack of defenses, limited experience in dealing with genetics and the growing disparities within the profession in implementing new medical technologies. The history of liability for genetic testing, primarily in the prenatal testing context, suggests that liability will often be both unpredictable and influential in changing medical practice. It is critical to anticipate and attempt to prevent such liability risks in a proactive manner so to minimize the disruptive impact that liability can cause.
责任很可能是个性化医疗未来发展方向和实施的主要驱动因素，促使基因检测和其他药物基因组学技术得到应用，在某些情况下是合理应用，而在其他情况下则是过早应用或作为低效的防御性医疗手段。虽然个性化医疗链中的所有实体都将面临责任风险，但医生面临的风险最大，因为他们缺乏防御措施，在处理遗传学方面经验有限，且在实施新医疗技术方面行业内差距日益增大。基因检测的责任历史，主要是在产前检测背景下，表明责任往往既不可预测，又会对医疗实践的改变产生影响。积极主动地预见并试图预防此类责任风险至关重要，以便将责任可能造成的破坏性影响降至最低。
